VSTM logo

VSTM
Verastem Inc

24,060
Mkt Cap
$427.82M
Volume
2.44M
52W High
$11.25
52W Low
$4.01
PE Ratio
-1.33
VSTM Fundamentals
Price
$5.81
Prev Close
$5.68
Open
$5.74
50D MA
$6.67
Beta
1.33
Avg. Volume
1.55M
EPS (Annual)
-$3.66
P/B
-24.42
Rev/Employee
$128,205.13
$138.07
Loading...
Loading...
Poll

Earnings Recap

• Reported GAAP EPS of -$0.39 up 70.68% YoY • Reported revenue of $17.54M • Verastem expects a cash runway into the first half of 2027, fueled by existing cash and product revenue. The company aims to accelerate VS-7375 clinical development and report RAMP 301 trial topline data in mid-2027.

Bullish

Verastem achieved $30.9 million in full year 2025 product revenue from AVMAPKI FAKZYNJA CO-PACK after accelerated FDA approval. Its VS-7375 pipeline showed encouraging safety, and GFH375 received Breakthrough Therapy Designation in China.

Bearish

Verastem faces NCCN guideline limitations for its key product, increased operating expenses due to R&D and commercialization, and a higher GAAP net loss of $209.5 million for the full year 2025.

Latest VSTM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.